Please login to the form below
cell and gene therapy
This page shows the latest cell and gene therapy news and features for those working in and with pharma, biotech and healthcare.
UK to introduce new regulatory framework for point of care manufacturing
The framework will apply to all POC products manufactured in the UK, including a range of advanced therapy medicinal products, including cell therapy, gene therapy and tissue engineered products. ... care, which will allow easier access to a greater and
Latest news
-
bluebird bio’s beta-thalassaemia gene therapy receives FDA approval
Due to the complex nature of gene therapy, Zynteglo will be available exclusively at qualified treatment centres, selected based on expertise in relevant areas such as stem cell transplantation, cell and ... gene therapy, and beta-thal.
-
bluebird bio reveals plans to launch two gene therapies
Both therapies were endorsed by the US FDA Cell Tissue &Gene Therapy Advisory Committee. ... The news comes after both therapies were endorsed by the US Food and Drug Administration (FDA) Cell Tissue &Gene Therapy Advisory Committee (CTGTAC) in June 2022.
-
Merck KGaA announces launch of start-up collaboration programme in Asia
Merck. The company noted that there will be a strong focus on companies working in manufacturing, utilising cellular, molecular- and immuno-assays or cell and gene therapy tools, engaging in manufacturing ... specialties such as supply chain innovation,
-
Bespoke Gene Therapy Consortium created to collaborate in development of rare disease gene therapies
The Bespoke Gene Therapy Consortium (BGTC) aims to change that. Bringing together ten pharma companies with the FDA, National Institutes of Health and five non-profit organisations, the BGTC aims to ... The non-profit partners include the Alliance for
-
bluebird bio provides update on 2seventy bio spin-off
advance the transformative gene and cell therapy products that sit on both sides of the current business.”. ... a healthy foundation to enable the continued advancement of our cell therapy platform.”.
More from news
Approximately 41 fully matching, plus 56 partially matching documents found.
Latest Intelligence
-
Meeting healthcare’s rising challenges
which time 80% of older people will be living in low- and middle-income countries. ... The promise is appealing, with a McKinsey report forecasting that healthcare innovations – from digital tools to gene and cell therapy – could reduce the total
-
CAR-T cell therapy in oncology
In working with oncology CAR-T therapies, the stakes for an efficient cell and gene therapy (CGT) supply chain are especially high because recipients are often in the later stages of ... Brian Huber is Vice President, Drug Development and Tamie Joeckel
-
Building a brighter future with patient support programmes
The high-rise promise of cell and gene therapy is the new architecture, gleaming with patient-centric potential and transformative intent. ... Collaborating does lead to greater things and it is exciting to see what developments in cell and gene therapy
-
Listen, learn and lift off
The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are expecting a busy year for approvals, with frantic activity in orphan diseases as gene and cell therapy ... Mead still believes HCPs will demand data and learning from
-
Keeping up with the developing regulatory requirements for gene and cell therapies
A crucial challenge faced by cell and gene therapy developers is the necessity to balance clinical considerations with logistical ones such as manufacturing. ... That’s why developers have started exploring other techniques, for example using a
More from intelligence
Approximately 2 fully matching, plus 19 partially matching documents found.
Latest appointments
-
Health comms agency emotive hires new cell and gene therapy leader
Dr Germano Ferrari. His most recent role was as a programme manager at the UK’s Cell and Gene Therapy Catapult where he helped develop commercialisation pathways for several pre-clinical ... Dr Ferrari said “We have now reached a turning point where
-
Weekly industry appointments
GSK’s CSO cell and gene therapy heads for the exit, Gelesis adds to company, Abcam appoints Peter Allen and Joseph Swedish joins Mesoblast’s board. ... be a global leader in the development and commercialisation of cell and gene therapy treatments.”
-
Orchard Therapeutics appoints Mark Rothera as CEO
He said: “Now is an exciting time to be joining Orchard as the cell and gene therapy field is advancing successfully. ... The clinical data we’ve seen to date with Orchard’s therapy for ADA-SCID is exceptional, and the company has assembled and
-
Avita Medical appoints CEO
chief scientific officer, global business development and licensing, and chief scientific officer for its cell and gene therapy unit. ... and Genetic Therapy Inc. Lou Panaccio, chairman of Avita, said: “Mike’s expertise across the value chain in cell
-
apceth Biopharma appoints Dusan Kosijer as CFO
He said: “I am excited and honoured to be able to contribute to the company that operates successfully for almost 10 years in the fast-moving field of cell and gene ... successful track record as one of the leading CDMOs for complex cell and gene
More from appointments
Approximately 1 fully matching, plus 7 partially matching documents found.
Latest from PMHub
-
The challenges of reimbursement and innovative pricing for cell and gene therapies
The cell and gene therapy landscape is difficult to navigate when it comes to pricing and reimbursement. ... Additionally, the process of reimbursement for payers of cell and gene therapies comes down to how the products are used—whether in an
-
The fast-paced future of cell and gene therapies
Cell and gene therapies represent a paradigm shift in the development of pharmaceutical products. ... While there is significant innovation in this space, few cell and gene therapies reach the market.
-
The promised land of gene therapy: Commercialization of novel gene-editing technology in beta-thalassemia
Several manufacturers are developing novel treatments for the disease, including Vertex, which has partnered with CRISPR Therapeutics to develop a gene-editing treatment for beta-thalassemia and sickle cell. ... Earlier this year, the US Food and Drug
-
From Vision to Action: Medical Affairs’ Time to Lead is Now – Key Themes and Takeaways From the 2022 Medical Affairs Professional Society (MAPS) Global Annual Meeting
Cell &Gene Therapy (2). Medical Affairs Role-Specific Guidance (12). Digital Innovation (3). ... as journal articles, white papers, congress presentations, medical booths, websites, and social media.
-
Disrupting Cell Engineering with Non-Viral Modalities
Jessica Schwaber, Scientific Director, Cell &Gene Therapy, Avectas, explores her company’s unique cell engineering platform, the recent shift in cell &gene therapy commercial needs, current barriers to realizing the full ... potential of cell &gene
More from PMHub
Approximately 0 fully matching, plus 16 partially matching documents found.
Subscribe to our email news alerts
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- BMS will not launch cancer drug Opdualag in Germany due to pricing pressures
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- LEO Pharma enters clinical trial partnership with ICON
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- Roche’s Polivy backed by FDA Advisory Committee for lymphoma therapy
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- WHY ARE PATIENT SUPPORT PROGRAMMES NOT WORKING?
- THE EVOLVING ROLE OF PROCUREMENT?
- Origins' Solutions Offering Explained
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Alzheimer’s Association report highlights need to improve patient-physician communication
- Locus Biosciences announces first patient treated in urinary tract infection trial
- A relentless commitment to neuroscience
- Eli Lilly announces 70% cut to US insulin prices while also capping out-of-pocket costs
- Merck signs $922m deal with Opko Health unit for Epstein-Barr vaccine candidate
- Origins Insights Offering Explained
- Neurodiversity and healthcare communications – do we know enough and do we do enough?
PMHub
KVA
KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...
Latest intelligence
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
- WHY ARE PATIENT SUPPORT PROGRAMMES NOT WORKING?
- By offering patients knowledge, skills and confidence, they empower patients to be more actively involved in their health. Holistic support can help tackle adherence, mental health or anything else patients...
- THE EVOLVING ROLE OF PROCUREMENT?
- Procurement is evolving to reinforce its position as a strategic enabler of company growth. How can agency partners organisations to realise this?...
